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Abstract
Background: Corticosteroids are widely used to reduce the urine protein levels of patients with immunoglobulin A
nephropathy (IgAN). However, their potential preventive effects on end-stage kidney disease (ESKD) are unclear.
Methods: We previously performed a large-scale, long-term multicenter cohort study of patients with biopsy-
proven IgAN treated between 1981 and 2013 (n = 1923). Based on the results, we reported that corticosteroids
pulse therapy was potentially effective for the treatment of patients with an eGFR ≥30 ml/min/1.73m2 and a urine
protein amount of ≥1 g/gCr. In the present study, we extracted 766 patients with chronic kidney disease (CKD),
stage G3–G4 (15 ≤ estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73m2) from the same cohort. We
divided these patients into a steroid pulse (SP) group, oral steroid (OS) group, and no steroid (NS) group, and
analyzed the risk of end-stage kidney disease (ESKD) stratified by eGFR and urine protein (UP) amounts.
Results: Over the median long-term follow-up of 70 ± 115 months, 37.1% of the patients with UP ≥1.0 g/day and
11.2% of the patients with UP < 1.0 g/day reached ESKD. Among the patients with UP ≥1 g/gCr, the SP group
showed significantly better renal outcome (p < 0.001) than the OS and NS groups. In patients with UP < 1 g/gCr,
there were no differences in renal survival among the treatment groups. These trends appeared even in the CKD
stage G4 patients, and were also apparent in patients taking renin-angiotensin system inhibitors. The
unprecedented long-term observation period in this study may have been necessary to reveal the favorable effect
of corticosteroids on ESKD progression.
Conclusions: In our long-term multicenter study, Corticosteroids pulse therapy was associated with better renal
outcomes in IgAN patients with higher UP values, even if their eGFR values were low.
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Background
Immunoglobulin A nephropathy (IgAN), a form of glom-
erulonephritis characterized by the mesangial deposition
of immunoglobulin A (IgA), is the most common cause of
chronic nephritis around the world [1]. Since the 1980s,
corticosteroid administration has been used worldwide as
a treatment for IgAN, and many studies (including several
controlled trials) have analyzed the efficacy of corticoste-
roids for this purpose [2–11]. Almost all these studies re-
ported that corticosteroids therapy reduced the urine
protein level, which is a surrogate marker for progression
of renal impairment. However, there is little evidence of
an improvement in renal survival itself. Thus the indica-
tions, optimal treatment method, and effectiveness of cor-
ticosteroids administration for IgAN are unclear, and
controversy remains about this treatment approach.
In 1999, Pozzi et al. reported a randomized controlled
trial (RCT) of Corticosteroids pulse treatment for IgAN
patients with urine protein levels of 1.0–3.5 g/day [6,
12], with 3 days of intravenous corticosteroids adminis-
tration in months 1, 3, and 5. They reported that corti-
costeroids ameliorated the decline in renal function of
patients during the mean follow-up period of 5 years,
and the results of their RCT have provided important
evidence supporting the effectiveness of Corticosteroids
pulse treatment for patients with IgAN.
The results of more recent studies are quite complicated.
In 2015, Rausen et al. reported the results of the Stop-IgAN
RCT of immunosuppression treatment for IgAN [13]. They
stated that the administration of immunosuppressive drugs
including corticosteroids in addition to intensive supportive
care including renin-angiotensin inhibition did not improve
the decrease in the estimated glomerular filtration rate
(eGFR) in a 3-year follow-up. Several months after the
Stop-IgAN trial, Tesar et al. reported the European Valid-
ation Study of the Oxford Classification of IgAN
(VALIGA), noting that corticosteroids tended to improve
renal outcomes in a 10-year follow-up [14]. Several similar
studies excluded patients with reduced renal function.
In many cases of IgA nephropathy, worsening of renal
function takes a long time. Accordingly, a long-term co-
hort study may be the only way to reveal renal outcome,
especially for serious outcomes such as end-stage kidney
disease (ESKD). Therefore, we previously established a
large-scale and long-term multicenter cohort study of
patients with biopsy-proven IgAN, with a long-term me-
dian follow-up duration of 70.0 months [15]. Based on
the results of that study, we reported that steroid pulse
therapy with or without tonsillectomy was potentially ef-
fective for IgAN patients with chronic kidney disease
(CKD) stage G1–G3 and high urine protein levels [15].
Our analyses indicated that tonsillectomy did not seem
to enhance the benefit of corticosteroids monotherapy.
We thus considered that it would be important to
estimate the effectiveness of corticosteroids when used
alone.
However, the effectiveness of corticosteroids treatment
for IgAN patients with reduced renal function has
remained controversial. In the present study, therefore, we
examined the renal prognosis of patients with advanced
CKD from our previously established large-scale cohort.
Methods
Patient recruitment
We previously reported a multicenter retrospective cohort
study of biopsy-proven IgAN patients at four kidney cen-
ters in Japan: the University of Tsukuba, Toranomon Hos-
pital, Seirei Sakura Citizen Hospital, and Toranomon
Hospital Kajigaya [15]. The 1923 patients who underwent
a kidney biopsy at one of these centers during the period
from March 1, 1981 to December 31, 2013 were recruited.
Each patient’s observation began, and all baseline parame-
ters were recorded, at the time of the biopsy. The study’s
clinical endpoint was end-stage kidney disease (ESKD),
which was defined as the initiation of renal replacement
therapy. Renal replacement therapy, in turn, was defined
as dialysis or pre-emptive kidney transplantation, though
no patients underwent transplantation during our obser-
vation. Dialysis was initiated by a physician’s decision in
each patient, in accordance with the criteria generally used
for dialysis initiation in Japan, i.e., serum creatinine of
≥8 mg/dl, uremic symptoms, or lowered ADL due to
chronic renal failure. This practice did not vary over the
approximately 30-year study period. All patients were ob-
served until ESKD, death, or censoring. The mean
follow-up period of the whole cohort was 8.3 years.
We categorized the patients into three groups based
on the method of corticosteroids administration. The
steroid pulse (SP) group included patients who received
intravenous methylprednisolone (mPSL) pulse therapy
for at least 3 days in a row during their follow-up period.
Typical steroid pulse therapy in this study was adminis-
tered over a 3-week period, with a single course of
methylprednisolone (500 mg/day) for 3 days followed by
oral corticosteroids, according to the protocol reported
by Hotta et al. [7]. However, each patient’s protocol
could be altered by the treating physician according to
the patient’s status, since at the time of our study there
was currently no firm evidence or established regimen
to guide the administration of corticosteroids in patients
with IgA nephropathy. Thus, a single dosage of methyl-
prednisolone varied from 500 mg to 1000 mg, the num-
ber of doses varied from one to three courses in a single
treatment series, and the tapering schedules for the cor-
ticosteroids also varied.
The oral steroid (OS) group included the patients who
received corticosteroids without an intravenous pulse. The
no steroid (NS) group did not receive any corticosteroids.
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In light of our previous finding [15], we did not investigate
the influence of tonsillectomy.
From the 1923 patients in the total cohort, we extracted
the cases of the 764 patients with chronic kidney disease
(CKD), stage G3–G4 (15 ≤ eGFR < 60 mL/min/1.73m2) as
subjects for the present study. The eGFR was calculated
by the formula for Japanese created by Matsuo et al. [16].
Statistical analyses
We stratified the cases by the amount of urine protein
(UP), which was calculated as the urine protein to urine
creatinine ratio (g/gCr), and investigated the renal sur-
vival. The data are summarized as proportions (percent),
median (1st interquartile – 3rd interquartile) or means
(± standard deviation). Categorical variables were ana-
lyzed by Fisher’s exact test, and continuous variables by
Student’s t-test. The survival analysis was performed by
the Kaplan-Meier method and with the log-rank test.
Hazard ratios of ESKD were calculated according to a
Cox-proportional hazard model. All analyses were con-
ducted using the R software program, ver. 3.4.2 (The R
Foundation for Statistical Computing Platform: x86_64
-w64-mingw32/× 64 (64-bit)).
Results
The subjects’ baseline characteristics
Table 1 summarizes the baseline characteristics of the
764 subjects (319 females, 445 males). The mean age
was 50.3 ± 13.6 years. The median follow-up period was
70 months. The median UP at the time of the biopsy
was 0.95 g/gCr. The numbers of patients with CKD
stages G3a (45 ≤ eGFR < 60 mL/min/1.73m2), G3b
(30 ≤ eGFR < 45 mL/min/1.73m2), and G4 (15 ≤ eGFR
< 30 mL/min/1.73m2) were 397 (52.0%), 236 (30.9%),
and 131 (17.1%), respectively.
Higher ages, shorter follow-up periods, and greater UP
values were observed in the further-progressed G stages.
The proportions of patients administered corticosteroids
by each method were as follows. For the total subject
group (G3a, G3b and G4 patients), 16% (n = 121), 18%
(n = 139) and 66% (n = 504) of patients received SP, OS
and NS treatment, respectively. Among G3a patients,
the corresponding percentages were 14% (n = 56), 16%
(n = 64) and 70% (n = 277). In G3b patients, they were
16% (n = 38), 19% (n = 45) and 65% (n = 153). And in G4
patients, 21% (n = 27), 23% (n = 30) and 56% (n = 74) of
patients received SP, OS and NS therapy. Tonsillectomy
was performed in 80 (10%) patients. Most of them (n =
68) were treated by a combination with SP. Only 8 pa-
tients underwent tonsillectomy without steroid ad
ministration.
Approximately 27% of patients had received RAAS in-
hibitors. Only 1.6% of subjects received immunosuppres-
sive drugs other than corticosteroids.
Renal survival
During the follow-up period, 37.1% of the patients with
UP ≥1.0 g/day and 11.2% of the patients with UP <
1.0 g/day reached ESKD. Figure 1a and b show the
Kaplan-Meier curves of renal survival in the patients
with G3a, G3b and G4 CKD for each level of UP.
Among the patients with UP ≥1 g/gCr, the SP group
showed significantly better renal outcomes (p < 0.001)
compared to the CS and NS groups. Figure 1c shows the
Kaplan-Meier curves of renal survival in the patients
with G3a, G3b and G4 CKD with UP ≥1 g/gCr and tak-
ing renin-angiotensin system inhibitors. Even in this
subgroup, SP showed significantly better renal outcome.
On the other hand, in patients with UP < 1 g/gCr, there
were no significant differences in renal survival among
the three treatment groups.
Discussion
Previous studies of corticosteroids administration for
IgAN have reported several negative results, but there are
few long-term studies of this treatment. In typical cases of
IgA nephropathy, progression of ESKD can take one or
more decades. So, as a matter of course, only rare cases
reach ESKD within three-years of follow-up, as described
in the previous report from our institute [5] or the
STOP-IgAN report [13]. Therefore, a long-term observa-
tion period like that of the present study might have been
necessary to reveal the favorable effects of corticosteroids
administration in patients with IgAN. In our study, the fa-
vorable therapeutic effects of corticosteroids administra-
tion were apparent even in patients with moderate UP
(0.5–1 g/gCr) and advanced CKD (stage G4); however, the
number of these patients was small (n = 23).
There have been few investigations into the efficacy of
corticosteroids for IgAN patients with advanced CKD, be-
cause patients with reduced eGFR or creatinine clearance
(Ccr) have been excluded from most of the prospective
studies [6, 7, 9]. In 1986, Kobayashi et al. reported a co-
hort of IgAN cases with urine protein ≥1 g/day and com-
pared the annual decline of Ccr among patients
categorized by their initial Ccr [2–4]. In that study, in 14
patients with Ccr < 70 ml/min, the corticosteroids treat-
ment did not improve renal outcome at a 10-year
follow-up; however, the number of patients was insuffi-
cient to reach any definitive conclusions. Moreover, their
patients received corticosteroids by oral administration, so
these findings do not contradict our present results.
Moriyama et al. reported that, among a group of 60
patients with Ccr < 70 mL/min, higher urinary protein,
and active glomerular lesions, oral steroid treatment was
effective in 20 patients. Lv et al. reported that oral mPSL
(0.6–0.8 mg/kg/day) conferred an increased risk of ser-
ious adverse events in their IgAN patients, despite the
potentially favorable renal outcomes [17]. Although in
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VALIGA the effectiveness of corticosteroids seemed ap-
parent even in patients with eGFR ≤50 ml/min/1.73m2
[14], the method of corticosteroids administration was
not analyzed. Our present study may thus be the first re-
port detailing the potential of steroid pulse treatment for
IgAN with reduced renal function.
There are several limitations of our study to be consid-
ered. First, bias from potential differences among the
treatment groups should be mentioned. For example,
avoidance of corticosteroids treatment might be associ-
ated with comorbidities such as infection, diabetes, car-
diovascular disease or other physical conditions that
could affect CKD progression. Second, the speed of the
reduction of eGFR at the time of the biopsy was not
recorded, and we thus could not detect rapidly progres-
sive cases that might be responsive to corticosteroids.
Patients with an advanced CKD G-stage in our cohort
might have included rapidly progressive cases that
would not generally be considered “chronic”. Third,
we did not collect data about adverse events. In the
future, it will important to evaluate the risk of steroid
pulse treatment, which is considered safer than oral
corticosteroids therapy [18].
Finally, the fact that few patients received RAAS inhib-
itors might constitute a major limitation of this study. In
2003, Praga et al. reported the effectiveness of ACE in-
hibitors for IgAN patients with UP ≥0.5 g/gCr [19].
Since then, RAAS inhibitors have become a worldwide
Table 1 Baseline characteristics of the subjects at the time of the renal biopsy
Characteristic Whole
G3–4
CKD G stage Treatment
G3a G3b G4 Pulse (SP) Oral (OS) None (NS)
n 764 397 236 131 121 139 506
Age, years 50.3 ± 13.6 47.7 ± 13.8 52.3 ± 13.4 54.6 ± 12.8 49.3 ± 14.7 49.5 ± 13.2 50.8 ± 13.4
Gender
Female 319 (42) 171 (57) 90 (38) 58 (44) 45 (37) 53 (38) 221 (44)
Male 445 (58) 226 (43) 146 (62) 73 (56) 76 (63) 86 (62) 283 (56)
Follow-up, months 70 ± 115 86 ± 141 65 ± 103 44 ± 61 67 ± 81 88 ± 125 65 ± 121
eGFR, ml/min/1.73m2 43 ± 12 53 ± 4.2 38 ± 5.6 23 ± 4.5 41 ± 13 41 ± 13 44 ± 11
CKD G Stage
G3a 397 (52) 397 (100) – – 56 (46) 64 (46) 277 (55)
G3b 236 (31) – 236 (100) – 38 (31) 45 (32) 153 (30)
G4 131 (17) – – 131 (100) 27 (22) 30 (22) 74 (15)
UP, g/gCr 0.95 ± 1.4 0.70 ± 1.1 1.2 ± 1.7 1.8 ± 2.7 1.5 ± 1.9 1.8 ± 2.2 0.73 ± 1.1
< 1.0 385 (50) 248 (62) 94 (40) 43 (33) 47 (39) 45 (32) 309 (61)
≥ 1.0 363 (48) 141 (36) 136 (58) 86 (66) 74 (61) 94 (68) 195 (39)
sBP, mmHg 134 ± 19 129 ± 19 137 ± 20 140 ± 19 134 ± 17 135 ± 19 133 ± 20
dBP, mmHg 80 ± 13 78 ± 12 82 ± 13 83 ± 14 79 ± 12 80 ± 13 80 ± 13
RAAs inhibition
+ 209 (27) 104 (26) 70 (30) 34 (26) 62 (51) 55 (40) 92 (18)
- 313 (41) 173 (44) 85 (36) 55 (42) 59 (49) 83 (60) 172 (34
Corticosteroids
Pulse (SP) 121 (16) 56 (14) 38 (16) 27 (21) 121 (100) – –
Oral (OS) 139 (18) 64 (16) 45 (19) 30 (23) – 139 (100) –
None (NS) 506 (66) 277 (70) 153 (65) 74 (56) – – 506 (100)
Immunosuppressant
+ 10 (2) 4 (1) 5 (2) 1 (1) 4 (3) 6 (4) 0 (0)
- 513 (70) 274 (69) 151 (64) 88 (67) 117 (97) 132 (95) 264 (52)
NA 241 (28) 119 (30) 80 (34) 42 (32) 0 (0) 1 (1) 240 (48)
Tonsillectomy 80 (10) 46 (12) 26 (11) 8 (6) 68 (56) 4 (3) 8 (2)
CKD chronic kidney disease, eGFR estimated glomerular filtration rate, immunosuppressive drugs use of immunosuppressive drugs other than corticosteroids, NA
not available, None no corticosteroids were administered during the observation period, Oral corticosteroids were administrated only orally, Pulse corticosteroid-
pulse therapy was administered during the observation period, RAAs inhibition renin-angiotensin-aldosterone system inhibition (use of angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers, or mineralocorticoid blockers), UP urine protein to urine creatinine ratio (g/gCr)
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standard therapy for IgAN. Our present cohort included
patients treated in the 1980s–2000s, so the patient char-
acteristics may have differed from that of patients in the
2010s. Moreover, in Japan, RAAS inhibitors are not ap-
proved as medications for glomerulonephritis, but only
for treatment for hypertension or diabetic kidney dis-
ease. So it was difficult for us to use RAAS inhibitors for
non-diabetic patients with normal blood pressure. Re-
cently, following publication of the KDIGO guidelines,
the use of RAAS inhibitors has been increasing in Japan.
Though the benefit of pulse therapy was apparent even
if we extracted patients who received RAAS inhibitors,
this might be a limitation for interpreting our results.
In summary, among our study’s patients with UP ≥1 g/
gCr, those who were treated with steroid pulse (SP) ther-
apy showed the best renal outcomes. In light of this re-
sult, Corticosteroids pulse treatment was associated with
better renal outcomes in IgAN patients with higher UP
values, even if their eGFR values are low. A high urine
protein value might indicate disease with high activity
(which is responsive to immunosuppression) in contrast
to stable CKD with low UP values.
Conclusions
We showed the potential favorable effect of Corticoste-
roids pulse therapy on IgAN patients with reduced renal
function. We need to create a unified regimen of Corti-
costeroids pulse therapy for IgAN in order to identify
predictors for corticosteroids sensitivity, and we must
determine the precise effectiveness and safety of this
therapy.
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